Amgen FY2026 EPS Forecast Increased by Cantor Fitzgerald

Key Points

• Cantor Fitzgerald has raised its FY2026 earnings per share forecast for Amgen to $21.75, up from a previous estimate of $21.47, while maintaining a "Neutral" rating and a target price of $305.00.
• Amgen's latest earnings report revealed an EPS of $6.02 for the quarter, beating expectations by $0.74, and the company reported a 9.4% year-over-year revenue increase.
• The firm recently declared a quarterly dividend of $2.38 per share, resulting in an annualized dividend yield of 3.2%.

Amgen Inc. (NASDAQ:AMGN - Free Report) - Investment analysts at Cantor Fitzgerald boosted their FY2026 earnings per share estimates for shares of Amgen in a research note issued on Wednesday, August 13th. Cantor Fitzgerald analyst C. Gould now expects that the medical research company will post earnings of $21.75 per share for the year, up from their previous forecast of $21.47. Cantor Fitzgerald currently has a "Neutral" rating and a $305.00 target price on the stock. The consensus estimate for Amgen's current full-year earnings is $20.62 per share.

Other equities research analysts have also issued reports about the company. Royal Bank Of Canada reduced their target price on Amgen from $324.00 to $320.00 and set an "outperform" rating for the company in a report on Friday, May 2nd. Citigroup lifted their price target on Amgen from $305.00 to $310.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 6th. William Blair reaffirmed an "outperform" rating on shares of Amgen in a research report on Tuesday, June 24th. Erste Group Bank downgraded Amgen from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 8th. Finally, Mizuho lifted their price target on Amgen from $235.00 to $280.00 and gave the stock a "neutral" rating in a research report on Wednesday, May 7th. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $303.76.

Amgen Stock Performance

AMGN traded up $2.82 on Friday, hitting $293.11. The company had a trading volume of 597,764 shares, compared to its average volume of 2,865,984. The company's fifty day moving average price is $293.18 and its 200 day moving average price is $292.85. Amgen has a 1-year low of $253.30 and a 1-year high of $339.17. The company has a debt-to-equity ratio of 7.24, a current ratio of 1.31 and a quick ratio of 0.98. The stock has a market cap of $157.80 billion, a price-to-earnings ratio of 23.99, a price-to-earnings-growth ratio of 2.49 and a beta of 0.49.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its earnings results on Tuesday, August 5th. The medical research company reported $6.02 earnings per share for the quarter, topping the consensus estimate of $5.28 by $0.74. Amgen had a return on equity of 174.71% and a net margin of 18.96%. The firm had revenue of $9.18 billion during the quarter, compared to analyst estimates of $8.86 billion. During the same period in the previous year, the company earned $4.97 EPS. The company's revenue for the quarter was up 9.4% on a year-over-year basis.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, September 12th. Stockholders of record on Friday, August 22nd will be paid a dividend of $2.38 per share. This represents a $9.52 annualized dividend and a dividend yield of 3.2%. The ex-dividend date of this dividend is Friday, August 22nd. Amgen's dividend payout ratio is 77.84%.

Insider Activity

In related news, SVP Rachna Khosla sold 1,500 shares of the company's stock in a transaction dated Thursday, June 5th. The stock was sold at an average price of $289.68, for a total value of $434,520.00. Following the completion of the sale, the senior vice president owned 8,162 shares in the company, valued at approximately $2,364,368.16. This represents a 15.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 0.76% of the stock is owned by company insiders.

Institutional Investors Weigh In On Amgen

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Beck Mack & Oliver LLC increased its holdings in Amgen by 0.7% in the fourth quarter. Beck Mack & Oliver LLC now owns 4,623 shares of the medical research company's stock valued at $1,205,000 after purchasing an additional 34 shares during the last quarter. Continuum Advisory LLC increased its holdings in shares of Amgen by 0.7% in the fourth quarter. Continuum Advisory LLC now owns 5,154 shares of the medical research company's stock worth $1,343,000 after acquiring an additional 35 shares in the last quarter. Octavia Wealth Advisors LLC increased its holdings in shares of Amgen by 1.5% in the first quarter. Octavia Wealth Advisors LLC now owns 2,435 shares of the medical research company's stock worth $759,000 after acquiring an additional 35 shares in the last quarter. Fairvoy Private Wealth LLC increased its holdings in shares of Amgen by 1.1% in the second quarter. Fairvoy Private Wealth LLC now owns 3,171 shares of the medical research company's stock worth $885,000 after acquiring an additional 35 shares in the last quarter. Finally, Nicholson Wealth Management Group LLC increased its holdings in shares of Amgen by 0.6% in the second quarter. Nicholson Wealth Management Group LLC now owns 5,918 shares of the medical research company's stock worth $1,652,000 after acquiring an additional 35 shares in the last quarter. Institutional investors own 76.50% of the company's stock.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.